These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 29845525

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE, de Silva AM.
    J Virol; 2017 Mar 01; 91(5):. PubMed ID: 28031369
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.
    VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC.
    PLoS Pathog; 2013 Mar 01; 9(12):e1003761. PubMed ID: 24348242
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.
    Swanstrom JA, Nivarthi UK, Patel B, Delacruz MJ, Yount B, Widman DG, Durbin AP, Whitehead SS, De Silva AM, Baric RS.
    J Infect Dis; 2019 Jun 19; 220(2):219-227. PubMed ID: 30895307
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection.
    Henein S, Adams C, Bonaparte M, Moser JM, Munteanu A, Baric R, de Silva AM.
    J Clin Invest; 2021 Jul 01; 131(13):. PubMed ID: 34003796
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE, Wallace D, Stinchcomb DT.
    Expert Rev Vaccines; 2016 Jul 01; 15(4):497-508. PubMed ID: 26635182
    [Abstract] [Full Text] [Related]

  • 18. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.
    Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS.
    Proc Natl Acad Sci U S A; 2014 Feb 04; 111(5):1939-44. PubMed ID: 24385585
    [Abstract] [Full Text] [Related]

  • 19. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD, Henein S, Kannadka CB, Barvir DA, Thomas SJ, de Silva AM, Jarman RG.
    Vaccine; 2018 Apr 25; 36(18):2403-2410. PubMed ID: 29602701
    [Abstract] [Full Text] [Related]

  • 20. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.
    de Silva AM, Harris E.
    Cold Spring Harb Perspect Biol; 2018 Jun 01; 10(6):. PubMed ID: 28716891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.